$EVLV

Evolv Technologies Holdings, Inc. (EVLV): Results of Operations and Financial Condition

Evolv Technologies Holdings, Inc. (EVLV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Evolv Technology Reports Second Quarter Financial Results — Company Adds 70 New Customers — — Company Raises Growth Estimates for 2026 — • Q2'26 Revenue of $43.8 million, up 34% year-over-year • Q2'26 Ending ARR 1 of $132.7 million, up 20% year-over-year • Q2'26 Net

Original reporting
Published Aug 11, 2026, 8:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$EVLV
Bullish
high confidence
Mentioned
$EVLV
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$EVLVBullishHigh
01

Why it matters

Traders can reprice the stock based on the combination of stronger Q2 ARR/revenue growth and a raised 2026 revenue, ending ARR, and adjusted EBITDA outlook, plus a stated shift in deployment mix toward purchase subscriptions.

02

Market read

The filing provides fresh, numeric guidance for 2026 and updated operating KPIs (ARR, adjusted EBITDA), which are direct inputs to valuation and near-term positioning.

03

What to watch

The filing notes a near-term gross margin headwind from upfront hardware cost recognition under the purchase subscription model, which could cap upside despite revenue/ARR growth.

Relevance 7/10Novelty 9/10Timing: after-hours filing, with a 4:30 p.m. ET conference call today

Background

This is an SEC 8-K with Exhibit 99.1 covering Evolv’s Q2 2026 results and an updated 2026 outlook, including ARR and adjusted EBITDA targets.

Company-level read

Ticker impact

$EVLVBullishHigh confidence
Context

Evolv reported Q2 revenue of $43.8M (+34% YoY), ending ARR of $132.7M (+20% YoY), and raised 2026 outlook.

Expected impact

Likely positive bias for the stock into the earnings call, with upside contingent on continued customer additions and ARR durability.

Evidence & confidence

The filing includes specific, time-sensitive guidance updates for 2026 (revenue $180-$185M, ending ARR $148-$150M, adjusted EBITDA $15-$16M) plus improved Q2 operating metrics (ARR growth, adjusted EBITDA inflection).

Market effects

Signals demand momentum for AI-enabled security screening and may support sentiment toward security tech and recurring-revenue software-like models.

Limited; company-specific results with no stated regional policy or procurement shift.

Limited; no international regulatory or cross-border deal disclosed.

Counterpoint

Guidance raises are paired with a still-material net loss, so the market may focus on cash burn and gross margin pressure from the higher purchase-subscription mix.

Key entities

  • Evolv Technologies Holdings, Inc.

    NASDAQ-listed security technology company reporting Q2 results and raising 2026 guidance.

  • John Kedzierski

    President and CEO quoted on customer additions and adoption trends.

  • Chris Kutsor

    CFO quoted on progress against the long-term framework and Rule of 50 objectives.

Related articles

$EVLVMed

Evolv Technologies Holdings, Inc. Q2 2026 Earnings Call Summary

Evolv Technologies Holdings reported 34% Q2 2026 revenue growth, citing new customer acquisition and completion of a direct fulfillment transition. Management raised full-year 2026 revenue guidance to 23% to 27% growth, expects over 10,000 units deployed by year-end, and remains cash-flow positive while potentially investing $2m to $4m in inventory safety stock.

$IBKRMedAI 8/10

Interactive Brokers Earns Interest on $182 Billion of Its Clients' Idle Cash. Will Anthropic's IPO Drain It?

Interactive Brokers (IBKR) reported $182.4B in uninvested client cash, up 27% YoY, earning interest until invested. Anthropic's potential $2T IPO could impact cash levels, but SpaceX's IPO didn't drain IBKR's reserves. IBKR's Q2 net interest income rose 23% to $1.06B, half of total revenues. Client accounts and trading activity grew, mitigating cash outflows. IBKR stock is near $92, trading at 29x next year's earnings.

$ORCLMedAI 8/10

Oracle’s AI Earnings Story Is Improving, but the Cash Flow Test Remains

Oracle (ORCL) reported strong Q4 earnings with 21% revenue growth and raised its profit forecast. Morgan Stanley increased its price target to $210, citing improved GPUaaS margins. However, the company faces cash flow pressure due to high capital expenditures for AI infrastructure, with free cash flow at negative $23.7 billion. Hedge funds remain invested, with Fisher Asset Management increasing its stake.

$AVGOMedAI 9/10

Broadcom’s AI Forecast Suggests Hyperscalers Want More Than Just Nvidia GPUs

Broadcom (AVGO) raised its AI chip revenue forecast to $115B for FY2027, up from $100B, and expects $230B in FY2028. This reflects Big Tech's demand for custom chips and networking components, reducing reliance on Nvidia (NVDA). KeyBanc reiterated an Overweight rating and $575 price target for AVGO. AVGO's Q3 revenue rose 86% YoY to $29.6B, but Q4 guidance was slightly below expectations. Hedge funds hold positions in both AVGO and NVDA, with Fisher Asset Management among the top holders.